Jakubowiak on Responses in Subgroups of Patients With Myeloma Who Received Cilta-Cel


In an interview at the 2021 ASH Annual Meeting, Andrzej Jakubowiak, MD, PhD, dives into response outcomes in different patient subsets of the phase 1/2b CARTITUDE-1 trial of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.

In an interview with CancerNetwork® at the 63rd American Society of Hematology Annual Meeting & Exposition, Andrzej Jakubowiak, MD, PhD, director of the Myeloma Program at University of Chicago Medicine, talked about different efficacy end points achieved with the use of ciltacabtagene autoleucel (cilta-cel) across subgroups of patients with relapsed/refractory multiple myeloma, data for which was derived from the phase 1/2b CARTITUDE-1 trial (NCT03548207).


The overall response rate was close to 100% and stringent complete response was 82%. MRD [minimal residual disease] rates were also in this range, specifically 92% in evaluable patients. I would start to answer this question by indicating that when we did the subgroup analysis, we looked at subgroups as follows: patients over 65, African Americans and Black, 3 and more than 4 lines of therapy, triple-class refractory, penta-drug refractory, [high] cytogenetic risks, ISS [International Staging System] stage 3, baseline bone marrow involvement of different [ranging from less than] 30% or more than 60%, BCMA [B-cell maturation antigen] expression, and presence of soft tissue plasmacytoma. These were the categories which we specifically analyzed in this context. The most important finding is that across all of these categories, response rates were almost identical, with this high 90% to 100% range. That’s an extremely important observation.

What we noted were some subtle differences in duration of response, progression-free survival, and overall survival, which trended slightly lower. Groups of patients with extramedullary plasmacytoma who had higher cytogenetics and were International Staging System 3 [had low responses], enough that we indicated in our conclusions that while these are maybe performing not as well as another groups, they still clearly outperform [on cilta-cel compared with] anything that we have available for this group of patients. That is an important observation. We see [across] all treatment modalities in myeloma that those patients may [experience] lower efficacy. Here, we have the same response rate, but indeed, there is a difference for duration response, progression-free survival, and overall survival.


Jakubowiak A, Usmani SZ, Berdeja J, et al. Efficacy and safety of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE-1 subgroup analysis. Blood. 2021;138(suppl 1):3938. doi:10.1182/blood-2021-146069

Related Videos
Administering immunotherapy following surgery in patients with early-stage triple-negative breast cancer does not appear to be as effective as beginning with neoadjuvant treatment, says Peter Schmid, MD, PhD.
Heather A. Parsons, MD, MPH, says she is excited about HER2 as a biomarker and investigating the biology of metastatic breast cancer with a minimally invasive liquid biopsy platform.
A panel of 4 experts on multiple myeloma seated at a long table
A panel of 4 experts on multiple myeloma seated at a long table
Saad Usmani, MD, MBA, FACP, an expert on multiple myeloma
Donna Catamero, ANP-BC, OCN, CCRC, an expert on multiple myeloma
Experts on MM
Related Content